The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Open accessAbstract
PURPOSE: Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells achieve durable responses. Consensus guidelines suggest avoiding bendamustine before apheresis, but specific data in this setting are lacking. We report distinct outcomes after CAR T-cell therapy according to previous bendamustine exposure. METHODS: The study included CAR T-cell recipients from seven European sites. Safety, efficacy, and CAR T-cell expansion kinetics were analyzed according to preapheresis bendamustine exposure. Additional studies on the impact of the washout period and bendamustine dose were performed. Inverse probability treatment weighting (IPTW) and propensity score matching (PSM) analyses were carried out for all efficacy comparisons between bendamustine-exposed and bendamustine-naïve patients. RESULTS: The study included 439 patients with R/R LBCL infused with CD19-targeted commercial CAR T cells, of whom 80 had received bendamustine before apheresis. Exposed patients had significantly lower CD3 + cells and platelets at apheresis. These patients had a lower overall response rate (ORR, 53% v 72%; P < .01), a shorter progression-free survival (PFS, 3.1 v 6.2 months; P = .04), and overall survival (OS, 10.3 v 23.5 months; P = .01) in comparison with the bendamustine-naïve group. Following adjustment methods for baseline variables, these differences were mitigated. Focusing on the impact of bendamustine washout before apheresis, those with recent (<9 months) exposure (N = 42) displayed a lower ORR (40% v 72%; P < .01), shorter PFS (1.3 v 6.2 months; P < .01), and OS (4.6 v 23.5 months; P < .01) in comparison with bendamustine-naïve patients. These differences remained significant after IPTW and PSM analysis. Conversely, the cumulative dose of bendamustine before apheresis did not affect CAR-T efficacy outcomes. CONCLUSION: Recent bendamustine exposure before apheresis was associated with negative treatment outcomes after CD19-targeted CAR T-cell therapy and should be therefore avoided in CAR T-cell candidates.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“were higher for participants treated with epcoritamab plus R² due to overlapping toxicities in line with previous reports of T-cell engaging immunotherapies.”
In the citing paper
“early-phase trials consistently reported complete response rates of more than 65%. 29-33”
Citations
Cites
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Austin, P. C., & Stuart, E. A. (2015) · Statistics in Medicine · doi:10.1002/sim.6607 · Cited by 4,495
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31366-0 · Cited by 2,430 · cited 2×
“%] and tisa-cel in 185 [42”
BackgroundLocke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, M., Neelapu, S. S., Farooq, U., Van Den Neste, E., Kuruvilla, J., Westin, J., Link, B. K., Hay, A., Cerhan, J. R., Zhu, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-769620 · Cited by 1,703
Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,510
Nastoupil, L. J., Jain, M. D., Feng, L., Spiegel, J. Y., Ghobadi, A., Lin, Y., Dahiya, S., Lunning, M., Lekakis, L., Reagan, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02104 · Cited by 801
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn, L. H., Herrera, A. F., Flowers, C. R., Kamdar, M. K., McMillan, A., Hertzberg, M., Assouline, S., Kim, T. M., Kim, W. S., Ozcan, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00172 · Cited by 774
Schuster, S. J., Tam, C. S., Borchmann, P., Worel, N., McGuirk, J. P., Holte, H., Waller, E. K., Jaglowski, S., Bishop, M. R., Damon, L. E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00375-2 · Cited by 584
Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
Hill, J. A., Li, D., Hay, K. A., Green, M. L., Cherian, S., Chen, X., Riddell, S. R., Maloney, D. G., Boeckh, M., & Turtle, C. J. (2018) · Blood · doi:10.1182/blood-2017-07-793760 · Cited by 576
Locke, F. L., Rossi, J. M., Neelapu, S. S., Jacobson, C. A., Miklos, D. B., Ghobadi, A., Oluwole, O. O., Reagan, P. M., Lekakis, L. J., Lin, Y., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002394 · Cited by 489
Rejeski, K., Perez, A., Sesques, P., Hoster, E., Berger, C., Jentzsch, L., Mougiakakos, D., Frölich, L., Ackermann, J., Bücklein, V., et al. (2021) · Blood · doi:10.1182/blood.2020010543 · Cited by 475
Self-citationPasquini, M. C., Hu, Z.-H., Curran, K., Laetsch, T., Locke, F., Rouce, R., Pulsipher, M. A., Phillips, C. L., Keating, A., Frigault, M. J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003092 · Cited by 450
Bachy, E., Le Gouill, S., Di Blasi, R., Sesques, P., Manson, G., Cartron, G., Beauvais, D., Roulin, L., Gros, F. X., Rubio, M. T., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01969-y · Cited by 405
Hay, K. A., Gauthier, J., Hirayama, A. V., Voutsinas, J. M., Wu, Q., Li, D., Gooley, T. A., Cherian, S., Chen, X., Pender, B. S., et al. (2019) · Blood · doi:10.1182/blood-2018-11-883710 · Cited by 404
Jacobson, C. A., Hunter, B. D., Redd, R., Rodig, S. J., Chen, P.-H., Wright, K., Lipschitz, M., Ritz, J., Kamihara, Y., Armand, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02103 · Cited by 352
Sehn, L. H., Chua, N., Mayer, J., Dueck, G., Trněný, M., Bouabdallah, K., Fowler, N., Delwail, V., Press, O., Salles, G., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30097-3 · Cited by 349
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.21.02370 · Cited by 331
Flinn, I. W., van der Jagt, R., Kahl, B., Wood, P., Hawkins, T., MacDonald, D., Simpson, D., Kolibaba, K., Issa, S., Chang, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00605 · Cited by 311
Hiddemann, W., Barbui, A. M., Canales, M. A., Cannell, P. K., Collins, G. P., Dürig, J., Forstpointner, R., Herold, M., Hertzberg, M., Klanova, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8960 · Cited by 240
Cytofluorometric methods for assessing absolute numbers of cell subsets in blood
Brando, B., Barnett, D., Janossy, G., Mandy, F., Autran, B., Rothe, G., Scarpati, B., D'Avanzo, G., D'Hautcourt, J.-L., Lenkei, R., et al. (2000) · Cytometry · doi:10.1002/1097-0320(20001215)42:6<327::aid-cyto1000>3.0.co;2-f · Cited by 231
Rejeski, K., Perez, A., Iacoboni, G., Penack, O., Bücklein, V., Jentzsch, L., Mougiakakos, D., Johnson, G., Arciola, B., Carpio, C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004475 · Cited by 202
Self-citationJain, T., Bar, M., Kansagra, A. J., Chong, E. A., Hashmi, S. K., Neelapu, S. S., Byrne, M., Jacoby, E., Lazaryan, A., Jacobson, C. A., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2019.08.015 · Cited by 191
Wang, Y., Jain, P., Locke, F. L., Maurer, M. J., Frank, M. J., Munoz, J. L., Dahiya, S., Beitinjaneh, A. M., Jacobs, M. T., Mcguirk, J. P., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01797 · Cited by 191
Sehn, L. H., Hertzberg, M., Opat, S., Herrera, A. F., Assouline, S., Flowers, C. R., Kim, T. M., McMillan, A., Ozcan, M., Safar, V., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005794 · Cited by 186
Jacobson, C. A., Locke, F. L., Ma, L., Asubonteng, J., Hu, Z.-H., Siddiqi, T., Ahmed, S., Ghobadi, A., Miklos, D. B., Lin, Y., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.05.026 · Cited by 186
Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors
Young, J.-A. H., Logan, B. R., Wu, J., Wingard, J. R., Weisdorf, D. J., Mudrick, C., Knust, K., Horowitz, M. M., Confer, D. L., Dubberke, E. R., et al. (2016) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2015.09.013 · Cited by 168
Di Blasi, R., Le Gouill, S., Bachy, E., Cartron, G., Beauvais, D., Le Bras, F., Gros, F.-X., Choquet, S., Bories, P., Feugier, P., et al. (2022) · Blood · doi:10.1182/blood.2022016945 · Cited by 167
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
Kwon, M., Iacoboni, G., Reguera, J. L., López‐Corral, L., Hernani, R., Ortiz‐Maldonado, V., Guerreiro, M., Caballero, A. C., Guerra-Domínguez, M. L., Pina, J. M. S., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.280805 · Cited by 150
Self-citationIacoboni, G., Villacampa, G. J., Martínez‐Cibrián, N., Bailén, R., López‐Corral, L., Sánchez, J. M. S., Guerreiro, M., Caballero, A. C., Mussetti, A., Sancho, J., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3881 · Cited by 137
Self-citationA national service for delivering CD19 CAR‐T in large B‐cell lymphoma – The UK real‐world experience
Kühnl, A., Roddie, C., Kirkwood, A. A., Tholouli, E., Menne, T., Patel, A. K., Besley, C., Chaganti, S., Sanderson, R., O'Reilly, M. A., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18209 · Cited by 130
Self-citationOutcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma
Tomás, A. A., Fein, J. A., Fried, S., Flynn, J. R., Devlin, S. M., Fingrut, W. B., Anagnostou, T., Alperovich, A., Shah, N. N., Fraint, E., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01739-2 · Cited by 107
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
Zurko, J. C., Ramdial, J., Shadman, M. S., Ahmed, S., Szabó, A., Iovino, L., Tomás, A. A., Sauter, C. S., Perales, M., Shah, N. N., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.281242 · Cited by 95
Monitoring CAR T‐cells using flow cytometry
Demaret, J., Varlet, P., Trauet, J., Beauvais, D., Grossemy, A., Hégo, F., Yakoub‐Agha, I., & Labalette, M. (2020) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21941 · Cited by 88
García‐Muñoz, R., Izquierdo-Gil, A., Muñoz, A., Galiacho, V. R., Rabasa, P., & Panizo, C. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2135-8 · Cited by 73
Saito, H., Maruyama, D., Maeshima, A. M., Makita, S., Kitahara, H., Miyamoto, K., Fukuhara, S., Munakata, W., Suzuki, T., Kobayashi, Y., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.86 · Cited by 67
Peinelt, A., Bremm, M., Kreyenberg, H., Cappel, C., Banisharif-Dehkordi, J., Erben, S., Rettinger, E., Jarisch, A., Meisel, R., Schlegel, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830773 · Cited by 64
García‐Recio, M., Wudhikarn, K., Pennisi, M., Alonso, R., Flynn, J. R., Shouval, R., Afuye, A. O., Silverberg, M. L., Batlevi, C. L., Dahi, P. B., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2020.10.022 · Cited by 60
Martínez‐Calle, N., Hartley, S., Ahearne, M. J., Kasenda, B., Beech, A., Knight, H. P., Balotis, C., Kennedy, B., Wagner, S. D., Dyer, M. J. S., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15722 · Cited by 56
Nydegger, A., Novak, U., Kronig, M.-N., Legros, M., Zeerleder, S. S., Banz, Y., Bacher, U., & Pabst, T. (2021) · Cancers · doi:10.3390/cancers13236073 · Cited by 28
Gaiolla, R. D., Hartley, S., Beech, A., Knight, H. P., Smith, D. A., Bishton, M. J., Fox, C. P., & Martínez‐Calle, N. (2020) · Hematological Oncology · doi:10.1002/hon.2797 · Cited by 7
Research works printed but not linked: 3
- Bethge WA, 2022, Blood, 140, 349
- Neelapu SS, 2023, Blood, 141, 2307
- van Buuren S, 2011, J Stat Softw, 45, 1
Cited by
Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02360-8 · Cited by 41
Metadata
- Authors
- Iacoboni, G., Navarro, V., Martín-López, A. Á., Rejeski, K., Kwon, M., Jalowiec, K. A., Amat, P., Reguera-Ortega, J. L., Gallur, L., Blumenberg, V., Gutiérrez-Herrero, S., Roddie, C., Benzaquén, A., Delgado-Serrano, J., Sánchez-Salinas, M. A., Bailén, R., Carpio, C., López-Corral, L., Hernani, R., Bastos, M., O'Reilly, M., Martín-Martín, L., Subklewe, M., & Barba, P.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Oncology Data Science (ODySey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
- Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain
- LMU Klinikum (DE)
- Hospital General Universitario Gregorio Marañón (ES)
- University Hospital of Bern (CH)
- Hospital Clínico Universitario de Valencia (ES)
- Hematology Department, Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain
- Universidad de Salamanca (ES)
- University College London (GB)
- Haematology Department, Hospital Clínico Universitario, Valencia, Spain
- Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Cancer Research Centre (IBMCC, USAL-CSIC), Institute for Biomedical Research of Salamanca (IBSAL) and Department of Medicine and Cytometry Service (NUCLEUS Research Support Platform), University of Salamanca (USAL), Salamanca, Spain
- ORCID
- Iacoboni, Gloria
- Navarro, Víctor
- Rejeski, Kai
- Kwon, Mi
- Jalowiec, Katarzyna Aleksandra
- Amat, Paula
- Gallur, Laura
- Blumenberg, Viktoria
- Gutiérrez-Herrero, Sara
- Roddie, Claire
- Benzaquén, Ana
- Sánchez-Salinas, Mario Andrés
- Bailén, Rebeca
- Carpio, Cecilia
- Hernani, Rafael
- Bastos, Mariana
- O'Reilly, Maeve
- Martín-Martín, Lourdes
- Subklewe, Marion
- Barba, Pere
- Venue
- Journal of Clinical Oncology
- Published
- 2024-01-10
- Volume
- 42
- Issue
- 2
- Pages
- 205-217
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4387900511
- Cited by
- 143
- References
- 44
- Citations by year
- 2026: 40 · 2025: 53 · 2024: 41
- FWCI
- 17.44
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Open Access CRIS of the University of Bern
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- bendamustine, large B-cell lymphoma, relapsed/refractory lymphoma, CAR T-cell therapy, CD19 CAR T cells, apheresis, overall response rate, progression-free survival, overall survival, drug-drug interactions, platelet count
- MeSH terms
- Bendamustine Hydrochloride, Receptors, Chimeric Antigen, Blood Component Removal, Humans, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Antigens, CD19, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.